Clinical Trial

Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression

Study acronym: ESKPSY
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 31, 2026 (before its estimated July 2026 completion). Its status may not reflect the trial's current state.
Summary
This observational study investigates the use of Esketamine Intranasal Spray in patients with Treatment-Resistant Depression in Real-World Settings. The study aims to evaluate the clinical outcomes, including efficacy and safety, of esketamine treatment. It also explores predictors of treatment response, focusing on biological pathways such as genetics, neuroimaging, and psychophysical measures. Additionally, the study examines how esketamine impacts patients' life functioning, including social and occupational aspects. The goal is to better understand who benefits most from esketamine and how it affects daily life, to improve personalized care for patients with difficult-to-treat depression.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-20; most recent amendment 2026-03-25.
Trial Details
NCT Number NCT07146503
Lead Sponsor Riccardo Guglielmo
Conditions Depression and Quality of Life, Treatment Resistant Depression (TRD), Anhedonia, Apathy, Anxiety, Cognition, Temperament, Psychiatric Comorbidities
Enrollment 100 participants
Start Date 2022-11-01
Primary Completion 2026-07 (estimated)
Study Completion 2030-08 (estimated)
Updated on ClinicalTrials.gov 2026-03-31